Palisade Bio

Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune, inflammatory, and fibrotic diseases. The company's history traces back to the founding of Leading BioSciences, Inc. on September 6, 2011. A significant milestone occurred in April 2021, when Leading BioSciences completed a reverse merger with Seneca Biopharma, Inc., creating the new, publicly traded entity named Palisade Bio. This strategic merger positioned the combined company to advance the clinical programs of the former Leading BioSciences. The company is headquartered in Carlsbad, California.

The company's leadership has seen transitions, with Thomas Hallam, Ph.D., who was instrumental in the development of its earlier assets, serving as CEO until October 2022. J.D. Finley, who had served as CFO since 2017 and played a key role in the merger, was appointed interim CEO and later confirmed as the permanent CEO in June 2023. Finley is an experienced financial executive who has been involved in raising nearly $1 billion for various companies throughout his career.

Palisade Bio's business is centered on the clinical development and future commercialization of therapeutics for gastrointestinal (GI) and inflammatory conditions with significant unmet medical needs. As a clinical-stage company, it currently does not generate revenue from product sales; its financial model is contingent on the successful development, regulatory approval, and commercialization of its product candidates, along with potential licensing agreements and partnerships. In September 2023, Palisade entered into an exclusive worldwide licensing agreement with Giiant Pharma, Inc., acquiring the rights to Giiant's proprietary prodrug platform and multiple product candidates targeting the inflammatory bowel disease (IBD) market. This agreement transformed Palisade's pipeline, shifting its focus toward autoimmune and inflammatory diseases.

The company's lead product candidate is PALI-2108, an orally administered, microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis (UC). This therapy is designed with a precision delivery technology to act directly in the colon, which could improve tolerability and enhance therapeutic effects compared to existing treatments. Another program from the Giiant license, PALI-1908, targets fibrostenotic Crohn's Disease. Palisade is also leveraging a precision medicine approach, using bioinformatics and machine learning in collaboration with specialists like Strand Life Sciences to identify patient stratification biomarkers, aiming to improve clinical outcomes.

Keywords: biopharmaceutical, clinical-stage, gastrointestinal diseases, inflammatory bowel disease, ulcerative colitis, Crohn's Disease, drug development, precision medicine, PDE4 inhibitor, prodrug, gut-restricted therapeutics, autoimmune diseases, fibrotic diseases, PALI-2108, Giiant Pharma, reverse merger, NASDAQ:PALI, JD Finley, Carlsbad, oral therapies, GI complications, drug licensing